Second quarter revenues increased 38 percent year-over-year
Sparsentan top-line data expected in third quarter of 2016
RE-024 efficacy trial expected to initiate in second half of 2016
- Net product sales for the second quarter of 2016 were
$33.3 million , compared to net product sales of$24.1 million for the same period in 2015 - Cash, cash equivalents, marketable securities, and notes receivable as of
June 30, 2016 totaled$315.2 million - Top-line data from the Phase 2 DUET study of sparsentan in focal segmental glomerulosclerosis (FSGS) remains on track to read out in the third quarter of 2016
- Trial evaluating the efficacy of RE-024 in pantothenate kinase-associated neurodegeneration (PKAN) remains on track to initiate in the second half of 2016
- Liquid formulation of ursodeoxycholic acid (L-UDCA) acquired in the second quarter of 2016; NDA filing for primary biliary cholangitis (PBC) indication expected in 2017
"We are very pleased with our strong second quarter performance, which was led by growth across all of our commercial products, and included the expansion of our pipeline," said
Quarter Ended
Net product sales for the second quarter of 2016 were
Selling, general and administrative (SG&A) expenses for the second quarter of 2016 were
Research and development (R&D) expenses for the second quarter of 2016 were
Total other expense for the second quarter of 2016 was
Tax benefit of
Net loss for the second quarter of 2016 was
As of
Commercial Product Updates
Thiola® (tiopronin)
- New patients continued to initiate treatment with Thiola during the second quarter of 2016.
Cholbam® (cholic acid)
- New patient growth with Cholbam continued during the second quarter of 2016.
- Uptake of the
Retrophin-sponsored Neonatal and Adult Cholestasis Sequencing Panel remained strong during the second quarter of 2016. The free genetic panel is expected to drive further awareness of bile acid synthesis disorders and Zellweger spectrum disorders and may enhance identification of new patients who could benefit from Cholbam therapy.
Chenodal® (chenodeoxycholic acid)
- New cerebrotendinous xanthomatosis (CTX) patients continued to initiate Chenodal treatment during the second quarter of 2016.
- Approximately 25 sites have been activated in the CTX prevalence study. The Company anticipates activating approximately 40 sites and enrolling up to 500 subjects in this multi-year study.
Pipeline Updates
Sparsentan
- Top-line data from the Phase 2 DUET study of sparsentan in FSGS are expected to read out in the third quarter of 2016, as previously reported.
RE-024
- The Company remains on track to initiate its efficacy trial evaluating RE-024 in PKAN during the second half of 2016.
- In the second quarter of 2016, Retrophin and collaborators presented new data at the 20th
International Congress of Parkinson's Disease and Movement Disorders suggesting RE-024 was safe and well tolerated in two adults with PKAN. Both patients experienced clinically meaningful improvements, followed by stabilization of disease symptoms over 47 weeks of treatment.
- The four PKAN patients receiving RE-024 under physician-initiated treatment outside of the
U.S. continue on therapy and remain stable.
Liquid ursodeoxycholic acid (L-UDCA)
- During the second quarter of 2016, the Company acquired the rights to L-UDCA. Retrophin intends to file a New Drug Application with the
U.S. Food and Drug Administration for the treatment of PBC in 2017, with the goal of making L-UDCA commercially available to the subset of PBC patients who have difficulty swallowing.
Conference Call Information
Retrophin will host a conference call and webcast today,
Use of Non-GAAP Financial Measures
To supplement Retrophin's financial results and guidance presented in accordance with
Investors should note that these non-GAAP financial measures are not prepared under any comprehensive set of accounting rules or principles and do not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP. Investors should also note that these non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future the Company may exclude other items, or cease to exclude items that it has historically excluded, for purposes of its non-GAAP financial measures; because of the non-standardized definitions, the non-GAAP financial measures as used by the Company in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by the Company's competitors and other companies.
As used in this press release, (i) the historical non-GAAP net income (loss) measures exclude from GAAP net income (loss), as applicable, revaluation of acquisition related contingent consideration, stock-based compensation expense, depreciation and amortization expense, change in fair value of derivative instruments; income tax provision; bargain purchase gain (ii) the historical non-GAAP SG&A expense measures exclude from GAAP SG&A expenses, as applicable, stock-based compensation expense, and depreciation and amortization expense; (iii) the historical non-GAAP R&D expense measures exclude from GAAP R&D expenses, as applicable, stock-based compensation expense, and depreciation and amortization expense.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Thiola®, Cholbam®, and Chenodal®.
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. In addition, expressions of our strategies, intentions or plans are also forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, success of its commercial products as well as risks and uncertainties associated with the Company's preclinical and clinical stage pipeline. Specifically, the Company faces risks associated with market acceptance of its marketed products including efficacy, safety, price, reimbursement and benefit over competing therapies. The risks and uncertainties the Company faces with respect to its preclinical and clinical stage pipeline include risk that the Company's research programs will not identify preclinical candidates for further development and risk that the Company's clinical candidates will not be found to be safe or effective. Specifically, the Company faces risk that the sparsentan Phase 2 clinical trials will fail to demonstrate that sparsentan is safe or effective; risk that the sparsentan Phase 2 program will be delayed for regulatory or other reasons, risk that RE-024 will not progress to Phase 2 or later clinical trials for safety, regulatory or other reasons; risk that the Company will be unable to file a New Drug Application for liquid ursodeoxycholic acid in 2017 or ever, risk that a New Drug Application for liquid ursodeoxycholic acid will not be approved for efficacy, safety, regulatory or other reasons, the risk that the Company will be unable to file an IND for RE-034 or initiate Phase 1 clinical trials for regulatory or other reasons, and for each of the programs risk associated with enrollment of clinical trials for rare diseases. The Company faces risk that it will be unable to raise additional funding required to complete development of any or all of its product candidates; risk relating to the Company's dependence on contractors for clinical drug supply and commercial manufacturing; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties as included in the Company's filings with the
| CONSOLIDATED BALANCE SHEETS | ||||||||
| (in thousands) | ||||||||
| Assets | (unaudited) | |||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 21,155 | $ | 37,805 | ||||
| Marketable securities | 200,359 | 191,799 | ||||||
| Accounts receivable, net | 16,566 | 12,458 | ||||||
| Inventory, net | 2,713 | 2,536 | ||||||
| Prepaid expenses and other current assets | 3,365 | 2,378 | ||||||
| Prepaid taxes | 8,499 | 8,107 | ||||||
| Note receivable, current | 47,500 | 46,849 | ||||||
| Total current assets | 300,157 | 301,932 | ||||||
| Property and equipment, net | 381 | 428 | ||||||
| Other asset | 1,859 | 1,859 | ||||||
| Intangible assets, net | 184,432 | 161,536 | ||||||
| 936 | 936 | |||||||
| Note receivable, long term | 46,206 | 45,573 | ||||||
| Total assets | $ | 533,971 | $ | 512,264 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 6,285 | $ | 7,639 | ||||
| Accrued expenses | 23,159 | 23,820 | ||||||
| Other current liabilities | 1,187 | 958 | ||||||
| Guaranteed minimum royalty | 2,000 | 2,000 | ||||||
| Business combination-related contingent consideration | 14,077 | 13,754 | ||||||
| Derivative financial instruments, warrants | 33,360 | 38,810 | ||||||
| Total current liabilities | 80,068 | 86,981 | ||||||
| Convertible debt | 44,092 | 43,766 | ||||||
| Other non-current liabilities | 2,548 | 3,066 | ||||||
| Guaranteed minimum royalty, less current portion | 8,488 | 8,885 | ||||||
| Business combination-related contingent consideration, less current portion | 72,300 | 45,267 | ||||||
| Deferred income tax liability, net | 12,103 | 24,328 | ||||||
| Total liabilities | 219,599 | 212,293 | ||||||
| Stockholders' Equity: | ||||||||
| Preferred stock |
— | — | ||||||
| Common stock |
4 | 4 | ||||||
| Additional paid-in capital | 381,687 | 365,802 | ||||||
| Accumulated deficit | (67,340 | ) | (65,153 | ) | ||||
| Accumulated other comprehensive income (loss) | 21 | (682 | ) | |||||
| Total stockholders' equity | 314,372 | 299,971 | ||||||
| Total liabilities and stockholders' equity | $ | 533,971 | $ | 512,264 | ||||
| CONSOLIDATED STATEMENT OF OPERATIONS | |||||||||||||||
| (in thousands, except share and per share data) | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three Months Ended |
Six Months Ended |
||||||||||||||
| 2016 | 2015 | 2016 | 2015 | ||||||||||||
| Net product sales | $ | 33,311 | $ | 24,068 | $ | 62,319 | $ | 41,440 | |||||||
| Operating expenses: | |||||||||||||||
| Cost of goods sold | 1,021 | 637 | 1,778 | 912 | |||||||||||
| Research and development | 17,675 | 10,563 | 32,347 | 20,910 | |||||||||||
| Selling, general and administrative | 23,205 | 19,692 | 42,330 | 34,547 | |||||||||||
| Change in valuation of contingent consideration | 2,789 | 120 | 5,485 | 120 | |||||||||||
| Total operating expenses | 44,690 | 31,012 | 81,940 | 56,489 | |||||||||||
| Operating loss | (11,379 | ) | (6,944 | ) | (19,621 | ) | (15,049 | ) | |||||||
| Other income (expenses), net: | |||||||||||||||
| Other income (expenses), net | (206 | ) | 522 | 4 | 349 | ||||||||||
| Interest expense, net | (147 | ) | (2,922 | ) | (309 | ) | (6,720 | ) | |||||||
| Finance expense | — | — | — | (600 | ) | ||||||||||
| Change in fair value of derivative instruments | (9,063 | ) | (29,418 | ) | 5,277 | (66,171 | ) | ||||||||
| Loss on extinguishment of debt | — | (2,250 | ) | — | (2,250 | ) | |||||||||
| Litigation settlement gain | — | 15,500 | — | 15,500 | |||||||||||
| Bargain purchase gain | — | — | — | 49,063 | |||||||||||
| Total other income (loss), net | (9,416 | ) | (18,568 | ) | 4,972 | (10,829 | ) | ||||||||
| Loss before provision for income taxes | (20,795 | ) | (25,512 | ) | (14,649 | ) | (25,878 | ) | |||||||
| Income tax benefit (expense) | 7,392 | (15 | ) | 12,462 | 40,006 | ||||||||||
| Net income (loss) | $ | (13,403 | ) | $ | (25,527 | ) | $ | (2,187 | ) | $ | 14,128 | ||||
| Net earnings (loss) per common share, basic | $ | (0.37 | ) | $ | (0.73 | ) | $ | (0.06 | ) | $ | 0.45 | ||||
| Net earnings (loss) per common share, diluted | $ | (0.37 | ) | $ | (0.73 | ) | $ | (0.20 | ) | $ | 0.44 | ||||
| Weighted average common shares outstanding, basic | 36,683,429 | 34,957,134 | 36,601,807 | 31,079,053 | |||||||||||
| Weighted average common shares outstanding, diluted | 36,683,429 | 34,957,134 | 38,063,285 | 34,827,405 | |||||||||||
| RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION | ||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| Three Months Ended |
Six Months Ended |
|||||||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||||||
| GAAP Operating Loss | $ | (11,379 | ) | $ | (6,944 | ) | $ | (19,621 | ) | $ | (15,049 | ) | ||||
| R&D Operating Expense | (17,675 | ) | (10,563 | ) | (32,347 | ) | (20,910 | ) | ||||||||
| Stock Compensation | 2,641 | 1,749 | 5,127 | 3,968 | ||||||||||||
| Amortization & Depreciation | 81 | 193 | 163 | 414 | ||||||||||||
| Subtotal non-GAAP items | 2,722 | 1,942 | 5,290 | 4,382 | ||||||||||||
| Non-GAAP R&D Expense | (14,953 | ) | (8,621 | ) | (27,057 | ) | (16,528 | ) | ||||||||
| SG&A Operating Expense | (23,205 | ) | (19,692 | ) | (42,330 | ) | (34,547 | ) | ||||||||
| Stock Compensation | 4,852 | 3,245 | 9,159 | 6,599 | ||||||||||||
| Amortization & Depreciation | 3,885 | 3,648 | 7,695 | 5,206 | ||||||||||||
| Subtotal non-GAAP items | 8,737 | 6,893 | 16,854 | 11,805 | ||||||||||||
| Non-GAAP SG&A Expense | (14,468 | ) | (12,799 | ) | (25,476 | ) | (22,742 | ) | ||||||||
| Change in valuation of contingent consideration | 2,789 | 120 | 5,485 | 120 | ||||||||||||
| Subtotal non-GAAP items | 14,248 | 8,955 | 27,629 | 16,307 | ||||||||||||
| Non-GAAP Operating Income | $ | 2,869 | $ | 2,011 | $ | 8,008 | $ | 1,258 | ||||||||
| GAAP Net Income (Loss) | $ | (13,403 | ) | $ | (25,527 | ) | $ | (2,187 | ) | $ | 14,128 | |||||
| Non-GAAP Operating Loss Adjustments | 14,248 | 8,955 | 27,629 | 16,307 | ||||||||||||
| Change in fair value of derivative instruments | 9,063 | 29,418 | (5,277 | ) | 66,171 | |||||||||||
| Bargain purchase gain | — | — | — | (49,063 | ) | |||||||||||
| Income tax benefit (expense) | (7,392 | ) | 15 | (12,462 | ) | (40,006 | ) | |||||||||
| Non-GAAP Net Income | $ | 2,516 | $ | 12,861 | $ | 7,703 | $ | 7,537 | ||||||||
| Per share data: | ||||||||||||||||
| Net gain (loss) per common share, basic | $ | 0.07 | $ | 0.37 | $ | 0.21 | $ | 0.24 | ||||||||
| Weighted average common shares outstanding, basic | 36,683,429 | 34,957,134 | 36,601,807 | 31,079,053 | ||||||||||||
Contact:Chris Cline , CFA Senior Director, Investor Relations 646-564-3680 IR@retrophin.com
Source:
News Provided by Acquire Media